Vaccines for Protection Against Mucosatropic Infections
Posted May 19 2011 8:00pm
Description of Invention: The invention offered for licensing and commercial development relates to the field of Vaccines. More specifically, the invention describes novel compositions, strategy and methods that can effectively induce local mucosal immune response (e.g. in a female genital tract that is infected with a mucosatropic pathogen), as well as systemic immune response. The method comprises administrating to the treated subject at least two (2) immunogenic compositions in a prime-boost regimen, each comprising an effective amount of an immunogen derived from the pathogen. The first composition is administered to the epithelial surface of the subject in combination with one or more agents or treatment to disrupt the epithelial surface (e.g.nonoxobol-9 or depot medroxyprogesterone acetate). The second immunogenic composition is administered systemically. The first composition is typically a papillomavirus pseudovirion (PsV) comprising a polynucleotide that encodes proteins on the mucosatropic pathogen. The PsV has shown to confer tropism for the basal epithelium and is uniquely capable of eliciting strong immune response at this environment. The immunogenic composition that is administered systemically is typically selected from one of the following groups: (a) a live attenuated virus (e.g. poxivirus) expressing a protein or proteins of the infecting pathogen, (b) a DNA vector encoding proteins of the pathogen, or (c) an immunogenic polypeptide from the pathogen.
Applications: Vaccines against infectious pathogens, particularly against mucosatropic pathogens and pathogens such as HIV, HCV, HSV or HPV that initiate infection at mucosal sites including the female genital tract.
The unique properties of the PsV vaccine vectors have shown to confer tropism for the basal epithelium, and are several folds more effective as mucosal vaccines compared with other DNA vaccines such as naked or vectored DNA.
The use of epithelial disruptive agent enhances the effectiveness of the PsV vaccines in mucosal tissues.
The unique vaccine compositions and the prime-boost vaccination strategy assure both local (i.e. vaginal track) and systemic immunity.
Development Status: Proof of principle has been demonstrated. Animal efficacy data in mice and primates is available.
Barney S. Graham, John T. Schiller, Christopher B. Buck, Jeffrey N. Roberts, Teresa R. Johnson, John D. Nicewonger, Rhonda C. Kines, and Man Chen. Use of HPV Virus-like Particles to Deliver Gene-based Vaccines. USPA 12/863,572 filed July 19, 2010. Priority date January 19, 2008 (USPA 61/022,324) and PCT/US2009/031600, filed January 21, 2009 (HHS Reference No. E-077-2008/0).
CB Buck, DV Pastrana, DR Lowy, JT Schiller. Efficient intracellular assembly of papillomaviral vectors. J Virol. 2004 Jan;78(2):751-757. [ PubMed: 14694107 ]
BS Graham, RC Kines, KS Corbett, J Nicewonger, TR Johnson, M Chen, D LaVigne, JN Roberts, N Cuburu, JT Schiller, and CB Buck. Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol. 2010 Sep;3(5):475-486. [ PubMed: 20555315 ]
Licensing Status: Available for licensing and commercial development.
Collaborative Research Opportunity: The Center for Cancer Research, Vaccine Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Vaccines for Protection Against Mucosatropic Infections. Please contact John Hewes, Ph.D. at 301-435-3121 or email@example.com for more information.
Portfolios: Cancer Cancer - Therapeutics Infectious Diseases Infectious Diseases - Vaccines
For Licensing Information Please Contact: John Stansberry Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-5236 Fax: 301-402-0220